PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 24, 2026Journal of the American Chemical Society1 citations

Group Competition Strategy for Covalent Ligand Discovery

View Full Paper
ZGZhihao GuoYMYunzhu MengBZBoyuan Zhao

Key Points

  • The aim is to develop a new strategy for comparing the binding abilities of covalent ligands in a proteome-wide context.
  • Introduced a group competition-based ABPP strategy (GC-ABPP) for direct ligand comparison.
  • Divided a library of fully functionalized probes into subgroups for simultaneous proteome labeling.
  • Assessed ligand-protein reactivity across over 6000 cysteine sites through multiple screening rounds.
  • Identified high-affinity ligands targeting BCAT2 and UGDH after three screening rounds.
  • Demonstrated the ability to compare multiple ligands against multiple proteins simultaneously.
  • Provided a new framework for iteratively selecting high-affinity ligands.

Abstract

As a powerful chemoproteomic tool, activity-based protein profiling (ABPP) has been extensively used for covalent ligand discovery. However, the current ABPP-based approaches are inherently based on indirect probe labeling competed by covalent ligands, and cannot directly compare the preferences of different ligands head-to-head. Herein, we report a group competition-based ABPP strategy (GC-ABPP) to allow the direct comparison of multiple ligands' binding ability on a proteome-wide scale. By dividing a library of fully functionalized probes (FFPs) into different subgroups and labeling the proteome simultaneously, the direct competition enables comparison of the labeling ability of different probes in drawing a global protein-ligand affinity metric. When it is applied to an expanded probe library, this strategy can be used iteratively to select the highest-affinity ligand toward a certain target protein in a multiple-round process. As a proof of concept, we synthesized 65 FFPs and employed the GC-ABPP to screen the ligand-protein reactivity for >6000 cysteine sites. After three rounds of screening, we identified high-affinity ligands targeting BCAT2 and UGDH. Our "multiple ligands versus multiple proteins" screening paradigm demonstrates great potential for applications in covalent ligand/drug discovery.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Guo et al. (2026) studied this question.

synapsesocial.com/papers/69746126bb9d90c67120b07chttps://doi.org/10.1021/jacs.5c18150
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase2006 · 682 citations
  2. 2Multistage Ultraviolet Photodissociation Mass Spectrometry To Characterize Single Amino Acid Variants of Human Mitochondrial BCAT22018 · 42 citations
  3. 3The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M2017 · 59 citations
  4. 4Covalent modification and active site-directed inactivation of a low molecular weight phosphotyrosyl protein phosphatase1992 · 68 citations
  5. 5The resurgence of covalent drugs2011 · 1,875 citations